Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 7,751 Shares

Key Points

• Director Quiros Juan Jose Chacon sold 7,751 shares on May 4 at an average price of $70.48 for $546,290, leaving him with 1,032,504 shares valued at about $72.8 million.
• He has sold roughly $15 million of Establishment Labs stock since late March across multiple transactions, indicating notable insider selling activity over the past two months.
• Establishment Labs shares traded around $70.24 with a $2.06 billion market cap; the company reported a quarterly EPS beat and 45.2% revenue growth but remains unprofitable, and analysts carry a consensus "Moderate Buy" with an average target of $86.86.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 7,751 shares of Establishment Labs stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $70.48, for a total transaction of $546,290.48. Following the completion of the transaction, the director directly owned 1,032,504 shares of the company's stock, valued at approximately $72,770,881.92. This trade represents a 0.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Friday, May 1st, Quiros Juan Jose Chacon sold 67,249 shares of Establishment Labs stock. The shares were sold at an average price of $70.78, for a total transaction of $4,759,884.22.
• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The shares were sold at an average price of $66.26, for a total transaction of $144,446.80.
• On Friday, April 24th, Quiros Juan Jose Chacon sold 30,178 shares of Establishment Labs stock. The shares were sold at an average price of $65.78, for a total transaction of $1,985,108.84.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The shares were sold at an average price of $65.43, for a total transaction of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The shares were sold at an average price of $65.23, for a total transaction of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total transaction of $2,048,730.75.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA traded up $0.01 during mid-day trading on Monday, reaching $70.24. 674,327 shares of the company were exchanged, compared to its average volume of 499,774. The company's 50-day simple moving average is $65.53 and its 200-day simple moving average is $66.03. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The stock has a market capitalization of $2.06 billion, a P/E ratio of -40.37 and a beta of 1.12. Establishment Labs Holdings Inc. has a twelve month low of $32.25 and a twelve month high of $83.31.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to analysts' expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. Establishment Labs's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.19) EPS. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of institutional investors have recently added to or reduced their stakes in the business. Elevation Point Wealth Partners LLC bought a new stake in Establishment Labs during the 1st quarter worth approximately $209,000. Patriot Financial Group Insurance Agency LLC grew its holdings in Establishment Labs by 20.4% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 5,450 shares of the company's stock worth $309,000 after acquiring an additional 925 shares during the last quarter. Cannon Global Investment Management LLC bought a new stake in shares of Establishment Labs in the 1st quarter valued at $738,000. Brian Low Financial Group LLC increased its position in shares of Establishment Labs by 10.2% during the first quarter. Brian Low Financial Group LLC now owns 4,598 shares of the company's stock worth $261,000 after buying an additional 424 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Establishment Labs by 134.3% during the first quarter. SG Americas Securities LLC now owns 37,928 shares of the company's stock worth $2,154,000 after buying an additional 21,742 shares during the period. 72.91% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ESTA. BTIG Research restated a "buy" rating and set a $88.00 target price on shares of Establishment Labs in a research note on Wednesday, April 29th. Needham & Company LLC lifted their price objective on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Tuesday, February 24th. Canaccord Genuity Group lifted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a "buy" rating in a research note on Thursday, February 26th. Wall Street Zen cut shares of Establishment Labs from a "buy" rating to a "hold" rating in a research note on Saturday, March 28th. Finally, Mizuho lifted their price objective on shares of Establishment Labs from $90.00 to $100.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $86.86.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.